<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000710</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 064</org_study_id>
    <secondary_id>11038</secondary_id>
    <nct_id>NCT00000710</nct_id>
  </id_info>
  <brief_title>A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex</brief_title>
  <official_title>A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety, pharmacokinetics (blood levels), and effectiveness of didanosine&#xD;
      (ddI) when administered both intravenously and orally. After the maximum tolerated dose (MTD)&#xD;
      is determined, an appropriate dosage regimen will then be established for Phase II and Phase&#xD;
      III trials.&#xD;
&#xD;
      Zidovudine (AZT) has produced the best clinical results in the drug therapy of AIDS to date,&#xD;
      but it produces toxicity in approximately 50 percent of patients. Early data show that ddI&#xD;
      possesses high antiviral activity and less toxicity than AZT. The most effective route and&#xD;
      dose of ddI has yet to be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Zidovudine (AZT) has produced the best clinical results in the drug therapy of AIDS to date,&#xD;
      but it produces toxicity in approximately 50 percent of patients. Early data show that ddI&#xD;
      possesses high antiviral activity and less toxicity than AZT. The most effective route and&#xD;
      dose of ddI has yet to be determined.&#xD;
&#xD;
      Patients are given intravenous drug for 14 days with a 1 day washout period, then 76 weeks of&#xD;
      oral medication. To expedite this safety study and still be able to maintain close monitoring&#xD;
      of the patient's health, an overlapping dosing regimen is used. After 6 patients have been&#xD;
      enrolled and at least 4 have completed 4 weeks of dosing without significant toxic effects, a&#xD;
      second group of patients is started at the next dose level.&#xD;
&#xD;
      AMENDED: An alternative oral dosing formulation of ddI will be provided as a buffer powder&#xD;
      blend packaged in sealed foil sachets in several strengths.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 1990</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>42</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Recommended:&#xD;
&#xD;
          -  Allopurinol for consistent occurrence of hyperuricemia observed with&#xD;
             2',3'-dideoxyinosine (ddI) administration.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis.&#xD;
&#xD;
          -  Oral acyclovir for herpes simplex infections provided ddI dosing is suspended during&#xD;
             this time.&#xD;
&#xD;
          -  Ketoconazole for patients not responding to any other therapy and after consultation&#xD;
             with the sponsor.&#xD;
&#xD;
          -  Symptomatic therapy such as analgesics, antihistamines, antiemetics, antidiarrheal&#xD;
             agents, or other supportive therapy may be administered as deemed necessary by the&#xD;
             principal investigator.&#xD;
&#xD;
          -  Aspirin rather than acetaminophen for fever.&#xD;
&#xD;
        Patients with the following will be included:&#xD;
&#xD;
          -  An absence of life-threatening opportunistic infection on enrollment.&#xD;
&#xD;
          -  A life expectancy less than 6 months.&#xD;
&#xD;
          -  Available for follow-up for at least 6 months.&#xD;
&#xD;
          -  Able to provide informed consent. Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Intractable diarrhea.&#xD;
&#xD;
          -  No venous access.&#xD;
&#xD;
          -  A history of or propensity for seizure disorders.&#xD;
&#xD;
          -  A history of past or current heart disease or other significant abnormality on routine&#xD;
             EKG.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Adenine deaminase inhibitors.&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole for Pneumocystis carinii pneumonia (PCP) infections.&#xD;
&#xD;
          -  Antibiotics.&#xD;
&#xD;
          -  Acetaminophen for therapy of fever.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Intractable diarrhea.&#xD;
&#xD;
          -  A life expectancy less than 6 months.&#xD;
&#xD;
          -  No venous access.&#xD;
&#xD;
          -  A history of or propensity for seizure disorders.&#xD;
&#xD;
          -  A history of past or current heart disease or other significant abnormality on routine&#xD;
             EKG.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes.&#xD;
&#xD;
          -  Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole.&#xD;
&#xD;
          -  Excluded within 1 month of study entry:&#xD;
&#xD;
          -  Any antiretroviral drug.&#xD;
&#xD;
          -  Investigational agents.&#xD;
&#xD;
          -  2',3'-didanosine.&#xD;
&#xD;
          -  AL721.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Immunomodulating drugs.&#xD;
&#xD;
          -  Excluded within 3 months of study entry:&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Cytotoxic agents.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Active alcohol or drug abuse sufficient in the investigator's opinion to prevent adequate&#xD;
        compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolin R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Demeter L, Nawaz T, Morse G, Dolin R, Reichman R. AZT resistant (AZT-R) HIV-1 isolates obtained during DDI monotherapy from a patient with no history of AZT use. Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:139</citation>
  </reference>
  <reference>
    <citation>Valentine FT, Seidlin M, Hochster H, Laverty M. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center. Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S534-9. doi: 10.1093/clinids/12.supplement_5.s534.</citation>
    <PMID>1974725</PMID>
  </reference>
  <reference>
    <citation>Lambert J, Dolin R, Seidlin M, Knupp C, McLaren C, Reichman RC. Phase I study of 2'3'dideoxyinosine(ddI) administered twice daily to patients with AIDS/AIDS related complex. Int Conf AIDS. 1989 Jun 4-9;5:563 (abstract no MCP130)</citation>
  </reference>
  <reference>
    <citation>Seidlin M, Lambert JS, Dolin R, Valentine FT. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS. 1992 Aug;6(8):831-5. doi: 10.1097/00002030-199208000-00011.</citation>
    <PMID>1418780</PMID>
  </reference>
  <reference>
    <citation>Lambert JS, Seidlin M, Valentine FT, Reichman RC, Dolin R. Didanosine: long-term follow-up of patients in a phase 1 study. Clin Infect Dis. 1993 Feb;16 Suppl 1:S40-5. doi: 10.1093/clinids/16.supplement_1.s40.</citation>
    <PMID>8093846</PMID>
  </reference>
  <reference>
    <citation>Dolin R, Lambert JS, Morse GD, Reichman RC, Plank CS, Reid J, Knupp C, McLaren C, Pettinelli C. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S540-9; discussion S549-51.</citation>
    <PMID>1974726</PMID>
  </reference>
  <reference>
    <citation>Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT, et al. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333-40. doi: 10.1056/NEJM199005103221901.</citation>
    <PMID>2139173</PMID>
  </reference>
  <reference>
    <citation>Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis. 1995 Dec;172(6):1480-5. doi: 10.1093/infdis/172.6.1480.</citation>
    <PMID>7594706</PMID>
  </reference>
  <reference>
    <citation>Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr (1988). 1992;5(1):60-4.</citation>
    <PMID>1346633</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Injections, Intravenous</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS-Related Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

